Psychosocial aspects and life project disruption in young women diagnosed with metastatic hormone-sensitive HER2-negative breast cancer.

Metastatic breast cancer (MBC) diagnosis in young women negatively impacts on quality of life (QoL) and daily activities, disrupting their life project and forcing them to face new psychosocial challenges. The recently published results on the improvement of the overall survival of pre- or perimenopausal women with hormone-receptor-positive, HER2-negative MBC treated with CDK4/6 inhibitors plus endocrine therapy, while preserving, and in some items improving their QoL, will change the landscape of the management of this patient population. Their extended survival and potential improvement in QoL will, therefore, modify their specific needs in terms of psychosocial support. The complexity of the care of young women with MBC is described herein, based on an extensive literature review. Further research about the specific psychosocial requirements of these women and a new multidisciplinary holistic approach is paramount to properly address their concerns and preferences. The communication with and support of their partners, parents and children is an important factor affecting the QoL of these patients. Altogether, a multidisciplinary care, open communication and personalized support is required to address the psychosocial implications of the new prognostic expectations on these patients with the incorporation of new targeted therapies.
Competing Interests: Declaration of competing interest Mireia Margelí Vila has received honoraria from Novartis, Pfizer, Pierre Fabre and Roche. Sonia del Barco Berron has received honoraria from Novartis. Miguel Gil-Gil has received honoraria from Daiichi, Eisai, Genentech, Novartis and Pfizer and reimbursement of congress travel expenses from Roche, Daiichi and Pfizer. Cristian Ochoa-Arnedo has received honoraria from Eisai and Novartis. Rafael Villanueva Vázquez has received honoraria from Novartis, Pfizer, Eisai and Roche.
(Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.)